Milk of Magnesia label update sharpens dosing and safety instructions for magnesium hydroxide
The latest DailyMed entry for Milk of Magnesia centers on a familiar agent with an unusually broad household role: magnesium hydroxide serves as both an antacid and a saline laxative. In the updated label, each 30 mL dose contains 2400 mg of magnesium hydroxide and is intended for oral use. The product is packaged as a white, spearmint-flavored suspension in unit-dose cups, a format that fits institutional distribution more than casual home use.
A single product carrying two indications demands careful attention to dose, timing, and patient selection. The label draws a clear boundary between short-term relief of dyspepsia-related symptoms and short-term management of constipation. In one setting, the suspension is meant to relieve heartburn, sour stomach, acid indigestion, and upset stomach associated with those symptoms. In the other, it is positioned for occasional constipation, with bowel movement typically occurring within 1/2 to 6 hours.
Magnesium hydroxide works by neutralizing acid and drawing water into the bowel
The pharmacology explains why one suspension can serve two very different complaints. As an antacid, magnesium hydroxide neutralizes gastric acid in the stomach, reducing the chemical irritation that drives heartburn and acid indigestion. As a saline laxative, it exerts an osmotic effect in the intestinal lumen, pulling water into the bowel and softening stool while promoting motility. The same chemistry can help or harm depending on the patient’s renal function, concurrent medications, and how long the drug is used.
The label therefore builds in several guardrails. Patients with kidney disease are told to ask a doctor before use, and the same caution applies to those on a magnesium-restricted diet. Renal clearance matters here because magnesium can accumulate when excretion is impaired, increasing the risk of toxicity in vulnerable patients. For a product sold over the counter, that warning is more than routine fine print; it is the main barrier against avoidable harm.
One sentence in the label carries particular bedside weight: the product may cause a laxative effect when used as an antacid. In practice, that means a patient seeking relief from reflux symptoms may get unexpected bowel activity even at doses chosen for upper gastrointestinal discomfort. The dual-action profile is useful, but it also makes patient counseling essential.
The label places hard limits on duration and daily volume
For antacid use, adults and children 12 years of age or older are directed to take 30 mL, up to twice daily, or as directed by a doctor. The maximum should not exceed 60 mL in a 24-hour period, and the label says the maximum dosage should not be used for more than 2 weeks except under the advice and supervision of a doctor. Those limits are important because repeated self-treatment can mask ongoing reflux disease, peptic pathology, medication-related gastritis, or another cause of persistent upper gastrointestinal symptoms.
The laxative instructions are more flexible in dose but stricter in follow-through. Adults and children 12 years of age or older may take 30 mL to 60 mL, either as a single daily dose or in divided doses, and each dose should be taken with a full glass of liquid. The same 60 mL ceiling applies in any 24-hour period. Children under 12 years of age are directed to ask a doctor. The warning against exceeding the recommended daily dose is not cosmetic; magnesium-based cathartics can provoke dehydration, electrolyte shifts, and cramping when overused.
The label also distinguishes occasional constipation from bowel symptoms that deserve medical review. Anyone with abdominal pain, nausea, vomiting, or a sudden change in bowel habits lasting more than 2 weeks is told to ask a doctor before use. If rectal bleeding occurs, or if no bowel movement follows use of the product, the instructions are to stop use and seek medical advice. A laxative should not become a substitute for evaluating obstruction, inflammatory bowel disease, colorectal lesions, or another underlying cause of altered stool pattern.
Renal risk, drug interactions, and pediatric caution shape real-world use
Interactions with prescription drugs are called out in both the antacid and laxative sections. Antacids can interfere with the absorption or timing of certain prescription therapies, so the label advises patients to consult a doctor or pharmacist if they are taking another medication. In real-world practice, that matters most when a patient is on drugs with narrow therapeutic windows or on treatments that depend on predictable gastrointestinal absorption.
Pregnancy and breastfeeding receive standard cautionary language as well. The label advises asking a health professional before use if pregnant or breast-feeding. It does not make claims about safety beyond that instruction, and it does not need to; the relevant clinical point is that magnesium hydroxide is not a thoughtless default in every physiologic state. It remains a medication with context-dependent use.
The packaging itself reinforces the intended use setting. This is a repackaged label distributed in 5 x 30 mL unit-dose cups, and the carton warning states that the package is not child resistant and is intended for institutional use only. Keep it out of the reach of children. The design suggests administration in settings where dosing can be supervised, a practical advantage when a product can act as either antacid or laxative and when dose repetition can quickly cross into excess.
Storage, inactive ingredients, and product identity are part of the safety profile
The label specifies storage at 20° to 25°C, or 68° to 77°F, with protection from freezing. It also states not to use the product if the seal on the cup is missing or torn. Those details may look administrative, but they matter for suspension stability, tamper detection, and integrity of use in institutional supply chains.
Inactive ingredients include cyclomethicone 4, hypromellose, methylparaben, potassium citrate, propylene glycol, propylparaben, water, saccharin sodium, and sorbitol. Flavoring is listed as spearmint, consistent with an oral suspension designed for palatability. The product information identifies the route of administration as oral and the marketing category as an OTC monograph drug under M007. The label is associated with Cardinal Health 107, LLC as packager and Cardinal Health as distributor.
Even without a trial table or comparative efficacy dataset, this label update carries clinical value. It confirms the concentration, the dosing ceiling, the duration limits, and the populations that need caution before use. For a drug as familiar as magnesium hydroxide, those details are the difference between routine symptom relief and preventable adverse effects.